Jorge Fabián Quarleri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/53125/publications.pdf

Version: 2024-02-01

68 papers 1,054 citations

471509 17 h-index 28 g-index

70 all docs

70 docs citations

times ranked

70

1567 citing authors

#	Article	IF	CITATIONS
1	Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. GeroScience, 2022, 44, 53-56.	4.6	52
2	SARS-CoV-2 interacts with renin-angiotensin system: impact on the central nervous system in elderly patients. GeroScience, 2022, , 1.	4.6	4
3	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience, 2022, 44, 57-61.	4.6	3
4	Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. GeroScience, 2022, 44, 2095-2103.	4.6	69
5	Mitochondrial Dynamics and VMP1-Related Selective Mitophagy in Experimental Acute Pancreatitis. Frontiers in Cell and Developmental Biology, 2021, 9, 640094.	3.7	12
6	Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine and Growth Factor Reviews, 2021, 58, 55-65.	7.2	11
7	Influence of aging on T cell response and renin-angiotensin system imbalance during SARS-CoV-2 infection. Immunology Letters, 2021, 232, 35-38.	2.5	O
8	Apoptosis in infectious diseases as a mechanism of immune evasion and survival. Advances in Protein Chemistry and Structural Biology, 2021, 125, 1-24.	2.3	16
9	Brucella abortus Infection Modulates 3T3-L1 Adipocyte Inflammatory Response and Inhibits Adipogenesis. Frontiers in Endocrinology, 2020, 11, 585923.	3.5	6
10	In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naÃ-ve HIV-infected men who have sex with men. Archives of Virology, 2020, 165, 2915-2919.	2.1	0
11	Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases. Frontiers in Immunology, 2020, 11, 1760.	4.8	2
12	An evaluation of the SARS-CoV-2 epidemic 16 days after the end of social confinement in Hungary. GeroScience, 2020, 42, 1221-1223.	4.6	2
13	Priming Astrocytes With HIV-Induced Reactive Oxygen Species Enhances Their Trypanosoma cruzi Infection. Frontiers in Microbiology, 2020, 11, 563320.	3.5	5
14	Antioxidant and neuroprotective effects of mGlu3 receptor activation on astrocytes aged in vitro. Neurochemistry International, 2020, 140, 104837.	3.8	7
15	Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis. Frontiers in Endocrinology, 2020, 11, 502.	3.5	20
16	SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 340.	3.9	65
17	Hepatic Stellate Cells and Hepatocytes as Liver Antigen-Presenting Cells during B. abortus Infection. Pathogens, 2020, 9, 527.	2.8	4
18	Longitudinal characterization of HIV-1 pol-gene in treatment-naÃ-ve men-who-have-sex-with-men from acute to chronic infection stages. Heliyon, 2020, 6, e05679.	3.2	1

#	Article	IF	CITATIONS
19	Brucella abortus Infection Elicited Hepatic Stellate Cell-Mediated Fibrosis Through Inflammasome-Dependent IL- $1\hat{l}^2$ Production. Frontiers in Immunology, 2019, 10, 3036.	4.8	24
20	Are the mechanisms involved in astrocyte and lymphocyte death during HIV infection similar?. Neural Regeneration Research, 2019, 14, 1707.	3.0	0
21	Cell Death Is Counteracted by Mitophagy in HIV-Productively Infected Astrocytes but Is Promoted by Inflammasome Activation Among Non-productively Infected Cells. Frontiers in Immunology, 2018, 9, 2633.	4.8	39
22	Astrocyte Apoptosis and HIV Replication Are Modulated in Host Cells Coinfected with Trypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2017, 7, 345.	3.9	6
23	Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. BioMed Research International, 2017, 2017, 1-12.	1.9	3
24	Genomic characterization and molecular evolution analysis of subtype B and BF recombinant HIV-1 strains among Argentinean men who have sex with men reveal a complex scenario. PLoS ONE, 2017, 12, e0189705.	2.5	6
25	CD4 ⁺ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients. World Journal of Hepatology, 2017, 9, 1073.	2.0	3
26	Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Annals of Hepatology, 2016, 15, 17-26.	1.5	10
27	Hepatitis B virus resistance substitutions: long-term analysis by next-generation sequencing. Archives of Virology, 2016, 161, 2885-2891.	2.1	9
28	Evolution of hepatitis C virus in HIV coinfected patients under antiretroviral therapy. Infection, Genetics and Evolution, 2016, 43, 186-196.	2.3	1
29	Virus evolution during chronic hepatitis B virus infection as revealed by ultradeep sequencing data. Journal of General Virology, 2016, 97, 435-444.	2.9	5
30	Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. International Journal of Antimicrobial Agents, 2015, 46, 219-224.	2.5	7
31	HIV-1 Tropism Dynamics and Phylogenetic Analysis from Longitudinal Ultra-Deep Sequencing Data of CCR5- and CXCR4-Using Variants. PLoS ONE, 2014, 9, e102857.	2.5	15
32	Inter and intra-host variability of hepatitis C virus genotype 1a hypervariable envelope coding domains followed for a 4–11 year of human immunodeficiency virus coinfection and highly active antiretroviral therapy. Virology, 2014, 471-473, 19-28.	2.4	6
33	HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. Journal of Medical Virology, 2014, 86, 64-70.	5.0	28
34	Hepatitis <scp>B</scp> virus depicts a high degree of conservation during the immuneâ€tolerant phase in familiarly transmitted chronic hepatitis <scp>B</scp> infection: deepâ€sequencing and phylogenetic analysis. Journal of Viral Hepatitis, 2014, 21, 650-661.	2.0	11
35	Increased in vitro glial fibrillary acidic protein expression, telomerase activity, and telomere length after productive human immunodeficiency virusâ€l infection in murine astrocytes. Journal of Neuroscience Research, 2014, 92, 267-274.	2.9	17
36	MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Scientific Reports, 2014, 4, 5915.	3.3	82

#	Article	IF	Citations
37	Core promoter: A critical region where the hepatitis B virus makes decisions. World Journal of Gastroenterology, 2014, 20, 425.	3.3	65
38	Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Archives of Virology, 2013, 158, 1907-1915.	2.1	3
39	Longitudinal HIV-1 gp120-C2V3C3 phylogenetic surveillance and tropism evolution in patients under HAART. Virus Genes, 2013, 46, 404-411.	1.6	1
40	Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 126-135.	1.3	34
41	HIV-1 Induces Telomerase Activity in Monocyte-Derived Macrophages, Possibly Safeguarding One of Its Reservoirs. Journal of Virology, 2012, 86, 10327-10337.	3.4	36
42	Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Archives of Virology, 2012, 157, 703-711.	2.1	14
43	Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. Antiviral Research, 2012, 94, 184-187.	4.1	11
44	Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Research, 2012, 95, 72-81.	4.1	8
45	Comparative analysis of hepatitis B virus genotype a molecular evolution in patients infected with HBV and HIV. Journal of Medical Virology, 2012, 84, 562-569.	5.0	8
46	A clustering phenomenon among HCVâ€1a strains among patients coinfected with HIV from Buenos Aires, Argentina. Journal of Medical Virology, 2012, 84, 570-581.	5.0	6
47	Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infectious Diseases, 2011, 11, 178.	2.9	8
48	Molecular characterization of hepatitis C virus genotype 4 sequences in HIVâ€coinfected patients from Argentina. Journal of Medical Virology, 2011, 83, 935-940.	5.0	8
49	The Hepatitis C Virus 5′UTR Genomic Region Remains Highly Conserved Under HAART: A 4- to 8-Year Longitudinal Study from HCV/HIV Co-Infected Patients. AIDS Research and Human Retroviruses, 2010, 26, 527-532.	1.1	5
50	Telomerase activity in peripheral blood mononuclear cells from HIV and HIV–HCV coinfected patients. Virus Research, 2010, 147, 284-287.	2.2	7
51	Hepatitis B Virus, Hepatitis C Virus and HIV Coinfection Among People Living With HIV/AIDS in Buenos Aires, Argentina. Sexually Transmitted Diseases, 2010, 37, 342-343.	1.7	17
52	Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV–HIV coinfected patients: A 3-yr prospective study. Journal of Clinical Virology, 2009, 46, 354-359.	3.1	20
53	Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antiviral Therapy, 2009, 14, 1175-1181.	1.0	5
54	Molecular characterization of hepatitis A virus in children with fulminant hepatic failure in Argentina. Liver International, 2008, 28, 47-53.	3.9	20

#	Article	IF	CITATIONS
55	Uncommon Hepatitis B Virus and/or Hepatitis C Virus Occult Infection in HIV-Positive Patients With Abnormal Level of Hepatic Enzyme. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 233-234.	2.1	1
56	Hepatitis B Virus Genotype Distribution and Its Lamivudine-Resistant Mutants in HIV-Coinfected Patients with Chronic and Occult Hepatitis B. AIDS Research and Human Retroviruses, 2007, 23, 525-531.	1.1	32
57	Molecular characterization of hepatitis A virus isolates from Argentina. Journal of Medical Virology, 2007, 79, 887-894.	5.0	9
58	HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors. Acta Gastroenterologica Latinoamericana, 2007, 37, 76-83.	0.1	16
59	High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children. Antiviral Therapy, 2007, 12, 1133-1138.	1.0	12
60	HLA class II involvement in HIV-associated Toxoplasmic encephalitis development. Clinical Immunology, 2005, 115, 133-137.	3.2	22
61	Drug Resistance Testing Provides Evidence of the Globalization of HIV Type 1: A New Circulating Recombinant Form. AIDS Research and Human Retroviruses, 2004, 20, 885-888.	1.1	25
62	Differences in Frequencies of Drug Resistance????Associated Mutations in the HIV-1 pol Gene of B Subtype and BF Intersubtype Recombinant Samples. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 207-209.	2.1	13
63	HIV Type 1 BF Recombinant Strains Exhibit Different pol Gene Mosaic Patterns: Descriptive Analysis from 284 Patients under Treatment Failure. AIDS Research and Human Retroviruses, 2004, 20, 1100-1107.	1.1	47
64	In Vitro Detection of Dissimilar Amounts of Hepatitis C Virus (HCV) Subtype-Specific RNA Genomes in Mixes Prepared from Sera of Persons Infected with a Single HCV Genotype. Journal of Clinical Microbiology, 2003, 41, 2727-2733.	3.9	8
65	Phylogenetic and Mathematical Analyses for Investigating Putative Mother-to-Infant Transmission Chains When Only GB Virus C (Hepatitis G Virus) 5′ Noncoding Region Sequences Are Available. Journal of Clinical Microbiology, 2003, 41, 4489-4491.	3.9	1
66	Hepatitis C Virus and GBV-C/Hepatitis G Virus in Argentine Patients with Porphyria Cutanea Tarda. Intervirology, 2001, 44, 215-218.	2.8	4
67	HIV Type 1 Genetic Diversity Is a Major Obstacle for Antiretroviral Drug Resistance Hybridization-Based Assays. AIDS Research and Human Retroviruses, 2001, 17, 1415-1421.	1.1	9
68	Genomic characterization of hepatitis C virus isolates from Argentina. Journal of Medical Virology, 1995, 47, 97-104.	5.0	24